About Concert Pharma
Concert Pharma is a Healthcare company based in Lexington (United States) founded in 2006, and was acquired by Sun Pharma in January 2023. Multiple drug candidates are developed for treating various diseases. Concert Pharma has raised $85.5 million across 3 funding rounds from investors including Sun Pharma, New Leaf Venture Partners and Flagship Pioneering. The company has 63 employees. Its chief executive, as recorded, is Roger Tung. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is CONCERT PHARMACEUTICALS, INC. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
The company was founded in 2006 and is headquartered in Lexington, United States, within the biotechnology sector. Drug candidates are developed by the firm to address multiple diseases, with operations focused on advancing therapies through clinical stages. The lead product, CTP-543, targets alopecia areata, an autoimmune dermatological condition. Additional candidates are pursued for other indications, supporting research and development efforts in pharmaceuticals.
- Headquarters Lexington, United States
- Employees 63
- Stage Acquired
- SectorsHealthcare
- Website concertpharma.com
- Social LinkedIn
- Acquired by Sun Pharma (Jan 2023)
- Legal Name Concert Pharmaceuticals, Inc.
- Annual Revenue$32.58 M (USD)312as on Dec 31, 2021
- Total Equity Funding$85.5M (USD)
in 3 rounds
- Latest Funding Round$65M (USD), Post-IPO
Nov 2021
- InvestorsSun Pharma
& 13 more
- Employee Count63
- Acquired bySun Pharma
(Jan 2023)
Funding Insights of Concert Pharma
Concert Pharma has successfully raised a total of $85.5M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $65 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $85.5M
- Total Rounds 3
- Last Round Post-IPO — $65M
- First Round $48.5M
(Nov 2006)
- Investors Count 13
All 3 funding rounds of Concert Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2021 | $65M | Post-IPO | – | – | |
| Apr 2008 | $37M | Series C | – | – | |
| Nov 2006 | $48.5M | Series B | – | – |
14 investors in total: 14 institutional.
Investors in Concert Pharma
Concert Pharma has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Sun Pharma, New Leaf Venture Partners and Flagship Pioneering.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
US private equity investments are managed by BVF Partners. | bvflp.com | San Francisco, United States | ||
Investment management in biotech, technology, energy, shipping, financials, and litigation sectors. | 2003 | qvt.com | ||
| mediphaseventure.com | ||||
Life science & tech focused VC firm investing in companies in the US | threearchpartners.com | San Mateo, United States | ||
US life sciences companies are invested in by Skyline Ventures. | skylineventures.com | Palo Alto, United States | ||
Capital is invested in life science innovations for healthcare transformation. | tvm-capital.com | Munich, Germany | ||
Venture capital firm focused on multiple sectors | brooksidecapital.com | San Francisco, United States | ||
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
Venture capital firm specializing in early-stage tech investments and founder support. | 1965 | greylock.com | ||
Life sciences-focused venture capital firm | 1999 | flagshippioneering.com | Cambridge, United States |
Investor details for Concert Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Concert Pharma
25 people are tracked at Concert Pharma (12 in leadership, 6 in board & advisors, 7 in team); the tracked headcount is 63.
| Name | Role | Group |
|---|---|---|
Roger Tung | CEO & President | Leadership |
James V. Cassella | Chief Development Officer | Leadership |
Nancy Stuart | Chief Operating Officer | Leadership |
Christine Boisclair | VP, Regulatory Affairs & Quality Assurance | Leadership |
Roger D. Tung | Co-Founder, President & CEO | Leadership |
Jeffrey A. Munsie | Chief Legal Officer | Leadership |
Nabil Uddin | VP, Corporate Development | Leadership |
Daniel Morse | VP, Global Supply Chain | Leadership |
Bob Zelle | VP Drug Development | Leadership |
Ken Goldenberg (Mitch) | Vice President, IT And Infrastructure | Leadership |
Mara Veverbrants Perry | Executive Director, Quality Assurance | Leadership |
K. Mitch Goldenberg | VP, IT & Infrastructure | Leadership |
Richard H. Aldrich | Chairman | Board & advisors |
Thomas G. Auchincloss Jr. | Board Member | Board & advisors |
Jesper Høiland | Board Member | Board & advisors |
Peter Barton Hutt | Board Member | Board & advisors |
Wilfred E. Jaeger | Board Member | Board & advisors |
Christine Van Heek | Board Member | Board & advisors |
Stephanie Gowing | Quality Assurance Specialist | Team |
Justine E. Koenigsberg | SVP, Corporate Communications & Investor Relations | Team |
5 more people are available in the full profile.
Complete people profiles for Concert Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Concert Pharma
5 dated milestones of Concert Pharma across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Concert Pharma is founded.
- Funding First funding round of $48.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $65.0M.
- Exit Acquired by Sun Pharma.
Competitors of Concert Pharma
Concert Pharma has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Concert Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Concert Pharma
Websites that share an audience with Concert Pharma (concertpharma.com).
Websites whose visitors overlap most with Concert Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
merrimackpharma.com | merrimackpharma.com | 100% | – | ||
| orexigen.com | 86% | View details | |||
| ptcbio.com | 86% | 24.4K | #1,154,739 | View details | |
watson.com | watson.com | 86% | #14,435,464 | – | |
| vrtx.com | 86% | 342.2K | #151,023 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 22 similar websites and full traffic analytics for Concert Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 22 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Concert Pharma (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Concert Pharma
Complete news archive for Concert Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Concert Pharma
Concert Pharma was founded in 2006.
Concert Pharma is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Roger Tung is the CEO of Concert Pharma, as recorded in our data.
Concert Pharma is a funded company, having raised a total of $85.5M across 3 funding rounds to date. The company's 1st funding round was a Series B of $48.5M, raised on Nov 2006.
Concert Pharma has 63 employees.
Annual revenue of Concert Pharma is $32.58M as on Dec 31, 2021.
The company was founded in 2006 and is headquartered in Lexington, United States, within the biotechnology sector. Drug candidates are developed by the firm to address multiple diseases, with operations focused on advancing therapies through clinical stages. The lead product, CTP-543, targets alopecia areata, an autoimmune dermatological condition. Additional candidates are pursued for other indications, supporting research and development efforts in pharmaceuticals.
Concert Pharma has 14 investors. Key investors include Sun Pharma, New Leaf Venture Partners, Flagship Pioneering, RA Capital, and Westfield Capital.
Concert Pharma operates through Concert Pharmaceuticals, Inc..
Yes. Concert Pharma was acquired by Sun Pharma in January 2023.